Document Type

Article

Publication Date

3-11-2018

Keywords

cellular therapy; cellular vehicle; glioblastoma multiforme; molecular envelope technology; oncolytic virus; temozolomide

Abstract

Glioblastoma multiforme (GBM) is the most common type of malignant primary brain cancer in adults. It is composed of highly malignant cells that display metastatic and angiogenic characteristics, making it resistant to current first-line chemotherapy with temozolomide, an alkylating agent. Despite many years of research, GBM remains poorly responsive to multiple available therapies, giving GBM patients, who receive the conventional combination of chemoradiotherapies and surgical resection, a dismal prognosis. There is growing evidence that the conventional systemic chemotherapeutic agents for GBM are ineffective in improving the disease progression. We aim to explore the emerging cellular therapies which may play a significant role in treating GBM.

Clinical Institute

Cancer

Clinical Institute

Neurosciences (Brain & Spine)

Department

Neurosciences

Department

Oncology

Share

COinS